BRAF and non-small cell lung carcinoma: At present, there are no data from randomized controlled trials comparing different first-line therapeutic strategies in BRAF mutated NSCLC and updated ESMO guidelines, although, when designating dabrafenib plus trametinib as the preferred regimen in a BRAF setting, it did not mention chemo-immunotherapy combinations, thus leaving this critical issue partly unanswered [29].